Morgan Stanley Call 105 SNW 20.12.../ DE000MB314D3 /
10/18/2024 8:44:06 PM | Chg.-0.021 | Bid10:00:39 PM | Ask10:00:39 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.249EUR | -7.78% | - Bid Size: - |
- Ask Size: - |
SANOFI SA INHABER ... | 105.00 - | 12/20/2024 | Call |
GlobeNewswire
9/2
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
8/26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
8/14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
8/13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
8/8
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
8/6
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
8/1
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
7/31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
7/25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
7/25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
7/24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
7/18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire
7/17
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire
7/12
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire
7/11
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire
7/8
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...